[Trandolapril in patients with left ventricular insufficiency after myocardial infarction]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Early post-myocardial infarction (MI) cardiac failure and left ventricular dysfunction (LVD) are associated with high mortality.
• Angiotensin-Converting Enzyme (ACE) inhibitors are a cornerstone of cardiovascular therapy, but their long-term benefit in early post-MI LVD requires further evaluation.

Purpose of the Study:

• To assess the efficacy of long-term treatment with trandolapril, an ACE inhibitor, in patients experiencing early cardiac failure following myocardial infarction.
• To determine if trandolapril reduces mortality and disease progression in this high-risk patient population.

Main Methods:

• The TRACE study randomized 1,749 patients with echocardiographic evidence of LVD (ejection fraction < 35%) within 3-7 days post-MI to receive either oral trandolapril or a placebo.
• Patients were followed for 24-50 months, with outcomes including all-cause mortality, cardiovascular death, sudden death, and progression to severe heart failure meticulously recorded.

Main Results:

• Trandolapril significantly reduced the overall risk of death by 22% (relative risk 0.78, p = 0.001) compared to placebo.
• The trandolapril group experienced significantly lower rates of cardiovascular death, sudden death, and progression to severe cardiac failure.
• No significant reduction in the risk of recurrent myocardial infarction was observed with trandolapril treatment.

Conclusions:

• Long-term administration of trandolapril is beneficial for patients with early post-MI left ventricular dysfunction.
• Trandolapril significantly improves survival and reduces the progression of heart failure in this vulnerable patient group.
• Trandolapril represents an effective therapeutic strategy for managing cardiac dysfunction after myocardial infarction.